William C. Dougall

14.5k citations

94 papers · 10.5k indexed · 4 hit papers · h-index 45

Impact in

Oncology top 0.2%
- Bone health and treatments
- Cytokine Signaling Pathways and Interactions
- Cancer Immunotherapy and Biomarkers
Cancer Research top 0.5%
- NF-κB Signaling Pathways

Papers in

Oncology 75
- Bone health and treatments 44
- Cytokine Signaling Pathways and Interactions 11
- Cancer Immunotherapy and Biomarkers 10
- HER2/EGFR in Cancer Research 8
Cancer Research 24
- NF-κB Signaling Pathways 23

Co-authors: Mark Tometsko David Cosman Dirk Anderson Laurent Galibert Mark J. Smyth Eileen R. Roux Mark Teepe Eugene Maraskovsky
Journals: Cancer Research (6 papers)Bone (4 papers)Journal of Biological Chemistry (4 papers)OncoImmunology (4 papers)Proceedings of the National Academy of Sciences (4 papers)
Partner nations: United States Australia Spain

In The Last Decade

William C. Dougall

93 papers receiving 10.3k citations

Hit Papers

align trajectories log scale

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab 2012 · 495 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Nature Reviews Drug Discovery
1999 Genes & Development
1997 Immunity
1997 Nature

Peers

Countries citing papers authored by William C. Dougall

Since Specialization

Citations

This map shows the geographic impact of William C. Dougall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William C. Dougall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William C. Dougall more than expected).

Fields of papers citing papers by William C. Dougall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William C. Dougall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William C. Dougall. The network helps show where William C. Dougall may publish in the future.

Co-authors

The 25 scholars most cited alongside William C. Dougall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William C. Dougall Line = papers co-authored together William C. Dougall links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	NMDAR antagonists suppress tumor progression by regulating tumor-associated macrophages Proceedings of the National Academy of Sciences ·Dongchen Yuan, Jing Hu, Xiaoman Ju, Eva Maria Putz, Simin Zheng, Stephane Koda, Guowei Sun, Xiaoran Deng, Zhipeng Xu, Wei Nie, Yang Zhao, Xian-Yang Li, William C. Dougall, Simin Shao, Yan Chen, Renxian Tang, Kuiyang Zheng, Juming Yan	2023	17
2	Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma Leukemia ·Mika Casey, Kane Segawa, Soi Cheng Law, Muhammed B. Sabdia, Bianca Nowlan, Basit Salik, Carol Lee, Clay Winterford, Sally‐Ann Pearson, Jason Madore, William C. Dougall, Maher K. Gandhi, Kyohei Nakamura	2022	16
3	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN) Trials ·Elizabeth Ahern, Annette Cubitt, E Ballard, Michele W.L. Teng, William C. Dougall, Mark J. Smyth, David Godbolt, Rishendran Naidoo, Amanda Goldrick, Brett Hughes	2019	22
4	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function Cancer Immunology Research ·Deepak Mittal, Ailin Lepletier, Jason Madore, Amelia Roman Aguilera, Kimberley Stannard, Stephen J. Blake, Vicki Whitehall, Cheng Liu, Mark Bettington, Kazuyoshi Takeda, Georgina V. Long, Richard A. Scolyer, Ruth Y. Lan, Nathan O. Siemers, Alan J. Korman, Michele W.L. Teng, Robert J. Johnston, William C. Dougall, Mark J. Smyth	2019	90
5	CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity OncoImmunology ·Amelia Roman Aguilera, Viviana P. Lutzky, Deepak Mittal, Xian-Yang Li, Kimberley Stannard, Kazuyoshi Takeda, Günter Bernhardt, Michele W.L. Teng, William C. Dougall, Mark J. Smyth	2018	42
6	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis OncoImmunology ·Heidi Harjunpää, Stephen J. Blake, Elizabeth Ahern, Stacey Allen, Jing Liu, Juming Yan, Viviana P. Lutzky, Kazuyoshi Takeda, Amy Roman Aguilera, Camille Guillerey, Deepak Mittal, Xian-Yang Li, William C. Dougall, Mark J. Smyth, Michele W.L. Teng	2018	37
7	RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation Cancer Research ·Guillermo Yoldi, Pasquale Pellegrini, Eva M. Trinidad, Álex Cordero, Jorge Gómez‐Miragaya, Jordi Serra-Musach, William C. Dougall, Purificacı́on Muñoz, Miguel-Angel Pujana, Lourdes Planelles, Eva González‐Suárez	2016	45
8	RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers Nature Medicine ·Emma Nolan, François Vaillant, Daniel Branstetter, Bhupinder Pal, Göknur Giner, Lachlan Whitehead, Sheau Wen Lok, G. Bruce Mann, Kathy Rohrbach, Liya Huang, R Soriano, Gordon K. Smyth, William C. Dougall, Jane E. Visvader, Geoffrey J. Lindeman	2016	186
9	RANK expression as a prognostic and predictive marker in breast cancer Breast Cancer Research and Treatment ·Berit M. Pfitzner, Daniel Branstetter, Sibylle Loibl, Carsten Denkert, Bianca Lederer, Wolfgang Schmitt, Frank Dombrowski, Martin Werner, Thomas Rüdiger, William C. Dougall, Gϋnter von Minckwitz	2014	47
10	RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis Cancer Research ·Marta Palafox, Irene Ferrer, Pasquale Pellegrini, Sergi Vila, Sara Hernández-Ortega, Ander Urruticoechea, Fina Climent, María Teresa Soler, Purificacı́on Muñoz, Francesc Viñals, Mark Tometsko, Dan Branstetter, William C. Dougall, Eva González‐Suárez	2012	153
11	Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab Nature Reviews Drug Discovery ·David L. Lacey, William J. Boyle, W. Scott Simonet, Paul J. Kostenuik, William C. Dougall, John K. Sullivan, Javier San Martín, Roger Dansey Hit paper breakdown →	2012	495
12	Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone Bone ·Mandeep S. Virk, Frank A. Petrigliano, Nancy Q. Liu, Arion F. Chatziioannou, David Stout, Christine O. Kang, William C. Dougall, Jay R. Lieberman	2008	34
13	RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model The Prostate ·Kathleen M. Woods Ignatoski, June Escara‐Wilke, Jiang’an Dai, Austin Lui, William C. Dougall, Stephanie Daignault, Zhi Yao, J. Zhang, Mark L. Day, Erin Sargent, Evan T. Keller	2008	23
14	RANKL Inhibition: From Mice to Men (and Women) Advances in experimental medicine and biology ·Marina Stolina, Paul J. Kostenuik, William C. Dougall, Lorraine A. Fitzpatrick, Debra Zack	2007	20
15	RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes The Prostate ·Allison Armstrong, Robert E. Miller, Jon C. Jones, Jian Zhang, Evan T. Keller, William C. Dougall	2007	142
16	Association of Signaling Proteins with a Nonmitogenic Heterodimeric Complex Composed of Epidermal Growth Factor Receptor and Kinase-Inactive p185 ^{c- neu} " DNA and Cell Biology ·William C. Dougall, Xiaolan Qian, Megan Miller, M.I. Greene	1996	10
17	Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation. PubMed ·Xiaolan Qian, William C. Dougall, Zhizhong Fei, M I Greene	1995	31
18	Down‐Regulation of c‐neu Receptors by Nerve Growth Factor in PC12 Cells Journal of Neurochemistry ·M. Oshima, Linnea A. Weiss, William C. Dougall, Mark I. Greene, Gordon Guroff	1995	11
19	The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. PubMed ·William C. Dougall, Xiaolan Qian, Norman Peterson, Megan Miller, Arabinda Samanta, Mark I. Greene	1994	158
20	Manganese Superoxide Dismutase: A Hepatic Acute Phase Protein Regulated by Interleukin-6 and Glucocorticoids* Endocrinology ·William C. Dougall, Harry S. Nick	1991	115

About William C. Dougall

William C. Dougall is a scholar working on Oncology, Cancer Research, Molecular Biology, Immunology and Orthopedics and Sports Medicine, having authored 94 papers that have together received 10.5k indexed citations. Recurring topics across this work include Bone Metabolism and Diseases (53 papers), Bone health and treatments (44 papers), NF-κB Signaling Pathways (23 papers), Cytokine Signaling Pathways and Interactions (11 papers), Cancer Immunotherapy and Biomarkers (10 papers), TGF-β signaling in diseases (10 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and HER2/EGFR in Cancer Research (8 papers). The work is most often cited by research in Oncology (6.5k citations), Cancer Research (2.4k citations), Orthopedics and Sports Medicine (1.1k citations), Immunology (2.3k citations) and Molecular Biology (6.6k citations). William C. Dougall has collaborated with scholars based in United States, Australia and Spain. Frequent co-authors include Mark Tometsko, David Cosman, Dirk Anderson, Laurent Galibert, Mark J. Smyth, Eileen R. Roux, Mark Teepe, Eugene Maraskovsky, Robert DuBose and Allison Armstrong. Their work appears in journals such as Cancer Research, Bone, Journal of Biological Chemistry, OncoImmunology and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact